Physician profile
Sameh A Labib
NPI 1962518969
$279,818.71
in general payments reported to CMS, 2019-2025
22 companies · $5,132 in 2025
The $5,132 reported for 2025 was more than what 81% of Sports Medicine (Orthopaedic Surgery) providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,647 · 2020: $130 · 2021: $197K · 2022: $1,683 · 2023: $24K · 2024: $46K · 2025: $5,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $67K · Food and Beverage: $4,988 · Travel and Lodging: $2,728 · Honoraria: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $67,130.00 |
| Food and Beverage | $4,988.32 |
| Travel and Lodging | $2,728.43 |
| Honoraria | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medshape, INC. | $191,416.40 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $37,365.22 | 2023-2025 | Exparel, Iovera, Zilretta |
| Fuse Medical, INC. | $20,875.91 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $13,606.73 | 2024 | |
| Heron Therapeutics, INC. | $4,528.17 | 2019-2021 | |
| International Life Sciences | $3,108.28 | 2023 | |
| United Orthopedics LLC | $2,318.00 | 2019-2022 | |
| Trilliant Surgical LLC. | $2,108.99 | 2021-2023 | Arsenal Ankle 10 Hole 1/3 Tubular Plate |
| Exactech, INC. | $2,083.69 | 2019-2023 | |
| Arthrex, INC. | $737.19 | 2019 | |
| Stryker Corporation | $583.69 | 2021-2024 | Inbone, Variax |
| Novastep INC. | $432.34 | 2021-2022 | |
| Treace Medical Concepts, INC. | $291.59 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $114.69 | 2023-2024 | Austedo Xr |
| Cerapedics INC. | $100.67 | 2024 | I-Factor Peptide Enhanced Bone Graft |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrosurface Incorporated | $57.96 | 2020 | |
| Anika Therapeutics, INC. | $21.67 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $19.62 | 2022 | |
| Mallinckrodt Hospital Products INC. | $16.61 | 2024 | Acthar |
| Bioventus LLC | $13.32 | 2019 | |
| Vericel Corporation | $11.35 | 2019 | |
| Trice Medical, INC. | $6.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$271,409.25 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameh Labib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.